Secondary Logo

Institutional members access full text with Ovid®

Bladder cancer risk in users of selected drugs for cardiovascular disease prevention

Guercio, Valentinaa; Turati, Federicaa,b; Bosetti, Cristinac; Polesel, Jerrye; Serraino, Diegoe; Montella, Mauriziof; Libra, Massimog; Galfano, Antoniod; La Vecchia, Carloa; Tavani, Alessandrac

European Journal of Cancer Prevention: March 2019 - Volume 28 - Issue 2 - p 76–80
doi: 10.1097/CEJ.0000000000000419
Research Papers: Urological Cancer

The aim of this study was to investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins, and calcium channel blockers (CCBs). We analyzed data from a multicentric case–control study carried out in Italy between 2003 and 2014, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) of bladder cancer and corresponding 95% confidence intervals (CIs) were estimated using unconditional multiple logistic regression models. The ORs for bladder cancer were 1.21 (95% CI: 0.87–1.68) for regular use of aspirin, 0.72 (95% CI: 0.54–0.97) for use of any CCBs, and 1.32 (95% CI: 0.87–1.99) for use of any statins. A slight inverse association was found with duration of use of CCBs, whereas no consistent association was found with duration of use, age at first use, and frequency for aspirin and statin use, or with indication of use for aspirin (as an analgesic or, for CVD prevention). No significant association was found for various combinations of drugs or for all drugs combined (OR=1.23, 95% CI: 0.31–4.85). Our data indicate the lack of a relevant association between the use of selected drugs for CVD prevention and bladder cancer risk, although suggest a potential favorable role for CCBs.

aDepartment of Clinical Sciences and Community Health, University of Milan

bDepartment of Medical Statistics, Biometry and Bioinformatics, National Cancer Institute

cDepartment of Epidemiology, IRCCS – The Mario Negri Institute for Pharmacological Research

dDepartment of Urology, Ospedale Niguarda Ca’Granda, Milan

eUnit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano

fUnit of Epidemiology, Cancer Institute G. Pascale Foundation Naples, Naples

gLaboratory of Translational Oncology and Functional Genomics, Section of General and Clinical Pathology and Oncology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy

Correspondence to Valentina Guercio, PhD, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy Tel: +39 025 032 0873; fax: +39 025 032 0866; e-mail:

Received April 21, 2017

Accepted July 13, 2017

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.